Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study
Ruoyang Shao,Yu Zhang,Jinping He,Fen Huang,Zhiping Fan,Kaibo Yang,Yajing Xu,Na Xu,Yi Luo,Lan Deng,Xi Zhang,Jia Chen,Mingzhe Han,Xudong Li,Sijian Yu,Hui Liu,Xinquan Liang,Xiaodan Luo,Pengcheng Shi,Zhixiang Wang,Ling Jiang,Xuan Zhou,Ren Lin,Yan Chen,Sanfang Tu,Jing Sun,Yu Wang,Qifa Liu,Li Xuan
DOI: https://doi.org/10.1038/s41392-023-01614-1
IF: 39.3
2023-09-14
Signal Transduction and Targeted Therapy
Abstract:Sorafenib therapy improves overall survival (OS) in patients with FLT3 internal tandem duplication (ITD) acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation. We explored the efficacy of sorafenib therapy in this population with different concomitant genetic patterns. In this multi-center, cohort study, we enrolled patients with FLT3-ITD AML undergoing allogenic hematopoietic cell transplantation. Patients with sorafenib maintenance post-transplantation for at least four weeks were allocated to the sorafenib group, and otherwise to the control group. Endpoints were OS, disease-free survival, and relapse for the whole cohort and OS for genetic pattern subgroups. Among 613 patients enrolled, 275 were in the sorafenib and 338 the control group. Median follow-up was 36.5 (interquartile range (IQR), 25.2–44.7) months post-transplantation. The 3-year OS post-transplantation was 79.6% (95% confidential interval (CI) 74.8%–84.6%) and 65.2% (95% CI 60.3%–70.6%) (Hazard ratio (HR) 0.50, 95% CI 0.37–0.69; P < 0.0001) in both groups. Sorafenib maintenance post-transplantation improved OS in the favorable (HR 0.33, 95% CI 0.14–0.77; P = 0.011) and adverse (HR 0.56, 95% CI 0.33–0.93; P = 0.026) ELN 2017 risk subgroups. Patients with mutated NPM1, DNMT3A, co-occurring NPM1/DNMT3A, "activated signaling" and "DNA methylation" genes benefited in OS from sorafenib maintenance, while those carrying CEBPA, "tumor suppressors" and "myeloid transcription factors" genes did not. Patients with FLT3-ITD high and FLT3-ITD low AML both benefited in OS from sorafenib maintenance. Our results identify the response of genetic patterns to sorafenib maintenance, providing new viewpoints for the optimal use of sorafenib in FLT3-ITD AML in the transplantation setting.
biochemistry & molecular biology,cell biology